ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Neurocrine Biosciences, Inc." (NBIX) Report Updated: Sep 26, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Neurocrine Biosciences, Inc." (NBIX)

Rating: Hold Volatility: Moderate
Total Grade: C Industry: Biotechnology
Competitors: MDVN,SPHS,PIP,EXEL

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: C down upgrade
Last Week: D same downgrade
Two Weeks Ago: C up no change
service keys

"Neurocrine Biosciences, Inc."© quotemedia

Company Profile

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The companyís products in clinical development stage include elagolix, which is in Phase III study for endometriosis and uterine fibroids; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2) that is in Phase III study for tardive dyskinesia, as well as in Phase II study for tourette syndrome; and NBI-640756, which is in Phase I study for essential tremor. Its research programs comprise Corticotropin-Releasing Factor Receptor1 Antagonist for congenital adrenal hyperplasia; VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for womenís and menís health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize valbenazine for movement disorders in Japan and other Asian markets; The Mount Sinai School of Medicine of the City University of New York to develop and commercialize licensed products worldwide; and Dainippon Sumitomo Pharma Co. Ltd. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.